Showing 1-1 of 1 result
Gordon Cohen M.D., M.P.H.
Funded: 07-01-2016 through 06-30-2018
Funding Type: St. Baldrick's Fellow
Institution Location: Baltimore, MD
Institution: Johns Hopkins University School of Medicine affiliated with Johns Hopkins Children's Center

Pediatric Philadelphia Chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) has a poor prognosis despite the introduction of Ph+ targeted drugs (TKIs). And for patients that fail to respond or relapse after TKIs, the prognosis remains grim. Dr. Cohen is studying why pediatric Ph+ ALL patients relapse (or fail to respond) to TKI treatment. Dr. Cohen has shown in early studies that combinations of TKIs and another new class of drugs can overcome TKI resistance. Because many of the drugs Dr. Cohen and his team are testing are commercially available, promising data from their research may move into future clinical trials.